Latest Content

New study links acne to higher eating-disorder risk, urging dermatologists and psychiatrists to spot warning signs and coordinate care.

Data and Safety Monitoring Board finds no safety issues for buntanetap at 6 months, keeping Annovis’ phase 3 early Alzheimer disease trial on track as enrollment progresses.

Explore how glutamate and GABA balance brain excitation and inhibition, shaping development, learning, and disorders like depression, schizophrenia, and autism.

APA shares DSM recommendations, and John J. Miller, MD, reviews and weighs in.

Learn how psychiatrists lead through change with emotional intelligence, mentorship, and early leadership roles that boost teamwork and patient safety.

Brief interpersonal therapy in pregnancy sharply lowers depression and postpartum relapse for a year—offering clinicians a fast, safe option.

A new liquid stimulant option promises up to 14-hour ADHD symptom control and flexible dosing for adults and kids who struggle with capsule medication.

A psychiatrist fights denials for GLP‑1 weight-loss drugs, exposing how high costs and rigid rules deepen obesity care inequities.

Denovo teams with Orygen to test DB103, a glutamate-targeting therapy, in a phase 2 youth trial for early psychosis.

Explore the new Psychiatric Times digital issue, featuring articles, multimedia, and interactive learning to sharpen your clinical skills.

Learn how bupropion can trigger dose-related tinnitus and when lowering or stopping the antidepressant brings relief, with real-world clinical guidance.

New evidence reframes antidepressant withdrawal: how common, how severe, and how to taper safely without mistaking symptoms for relapse.

FDA grants priority review to Takeda’s orexin agonist oveporexton, promising phase 3 gains in wakefulness and cataplexy for narcolepsy type 1.